Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
Imke H. Bartelink(University of California, San Francisco), Laura van ‘t Veer, Véronique Dartois(Hackensack Meridian Health), Byron Hann(University of California, San Francisco), Diane Heditsian(University of California, San Francisco), Lisa J. Wilmes(University of California, San Francisco), Douglas Yee(University of Minnesota Medical Center), Nela Pawłowska(University of California, San Francisco), Hilde Rosing(The Netherlands Cancer Institute), Ella F. Jones(University of California, San Francisco), Lamorna Swigart-Brown(UCSF Helen Diller Family Comprehensive Cancer Center), Bo Pan(First Affiliated Hospital Zhejiang University), Pei Rong Evelyn Lee, Ron J. Keizer(Slotervaartziekenhuis), Brendan Prideaux(Hackensack Meridian Health), Sergey Magnitsky(University of California, San Francisco), Laura J. Esserman(University of California, San Francisco), Scott Thomas(Memorial Hospital of South Bend), Alan H.B. Wu(University of California, San Francisco), Rahul Aggarwal(UCSF Helen Diller Family Comprehensive Cancer Center), Pamela N. Münster(University of California, San Francisco), Gregor Krings(Cleveland Clinic), Niels de Vries(The Netherlands Cancer Institute), Weiming Ruan(University of California, San Francisco), Jean-Philippe Coppé(University of California, San Francisco), Radojka M. Savić(University of California, San Francisco), Mallika Dhawan(University of California, San Francisco), Denise M. Wolf
Cited by 24
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k